Shepherd Therapeutics Information

SHEPHERD’s mission is to cure rare cancers. We work closely with rare-cancer specific disease foundations to identify and pursue the highest potential translational science. We then leverage those relationships to run clinical trials which are finely attuned to the specific needs of rare cancer patients. Our platform-agnostic approach allows us to select the most technologically innovative solutions for patients and to diversify our portfolio of lead compounds across rare cancers, therapeutic platforms, and partnership and licensing structures. SHEPHERD aims to be the development partner of choice for other biopharma companies looking to expand the application of therapeutic platforms and approaches into rare and orphan indications, but which encounter P&L and other business limitations preventing them from doing so. To learn more, visit shepherd.bio. BioSpace's Top 20 Companies to Watch in 2018 Forbes 30 Under 30